A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
NEW YORK, July 28, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on August 10, 2021 at 8:30 AM Eastern Time...
NEW YORK, July 07, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that the company will present at Access to Giving Virtual Conference. The...
NEW YORK, June 08, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell...
As Previously Disclosed, the Prespecified Primary Endpoint, Objective Response Rate, Has Been Met by Exceeding the 95% CI Lower Bound Threshold for Success Newly Disclosed Patient Level Data Demonstrates a 44% Best Overall Response for the HEPZATO Arm Versus 17% for...
NEW YORK, June 03, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced that management will present at: LD Micro Virtual Investor ConferenceDate:...
NEW YORK, May 26, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at: Jefferies Virtual Healthcare Conference on...
NEW YORK, May 11, 2021 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the first quarter ended March 31,...
NEW YORK, April 30, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on May 11, 2021 at 8:30 AM Eastern Time to...
A Presentation of Positive Preliminary Efficacy Results from the FOCUS Phase III trial Company Q&A Webinar Scheduled for Monday, June 7, 2021 at 8:30am ET NEW YORK, April 30, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused...
Recommends Special Arrangement Designation Which Increases Reimbursement OptionsNEW YORK, April 21, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that...
20.1% Lower Bound of Preliminary ORR Analysis Exceeds Required 8.3% ThresholdNEW YORK, March 31, 2021 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today provided...
NEW YORK, March 31, 2021 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter ended December...
Based on Preliminary Data, FOCUS Trial Achieves Prespecified Success Threshold Conference Call Today at 8:00am Eastern Time NEW YORK, March 31, 2021 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and...
NEW YORK, March 24, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today it will host a conference call on March 31, 2021 at 8:00 AM Eastern Time...
NEW YORK, March 08, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor...
NEW YORK, Feb. 11, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor...
NEW YORK, Jan. 11, 2021 -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced today that management will present at the H.C. Wainwright BIOCONNECT 2021...
NEW YORK, Dec. 11, 2020 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the completion of an underwritten public offering of 1,679,031 shares of...
NEW YORK, Dec. 09, 2020 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the pricing of an underwritten public offering of 1,460,027 shares of its...
NEW YORK, Dec. 08, 2020 -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced that it intends to offer and sell, subject to market conditions, shares of...
NEW YORK, Dec. 07, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced Kevin Muir has joined the company as Vice President of Commercial Operations....
Conference Call Today at 8:30am Eastern TimeNEW YORK, Nov. 11, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial...
NEW YORK, Nov. 02, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced management will participate in the Oppenheimer Fall MedTech Summit on Thursday,...
NEW YORK, Nov. 02, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today announced that it will host a conference call on November 11, 2020 at 8:30 AM Eastern Time...
Overall Response Rate of 72% observed in patients with metastases confined to the liverNEW YORK, Oct. 29, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, today...
Gerard Michel Brings the Experience Needed to Lead Delcath as it Transitions from a Development to Commercial Stage CompanyJohn Purpura Appointed Chief Operating Officer with Operational, Manufacturing and Regulatory Responsibilities NEW YORK, Oct. 01, 2020 -- Delcath...
NEW YORK, Sept. 10, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will participate in two upcoming virtual investor conferences:...
NEW YORK, Aug. 25, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will present at the LD Micro 500 Virtual Conference Tuesday,...
NEW YORK, Aug. 13, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announces financial results for the quarter ended June 30, 2020, and will host an earnings...
NEW YORK, Aug. 06, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that it will host a conference call on August 13, 2020 at 4:30 PM Eastern...
NEW YORK, Aug. 03, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that John Purpura, interim Chief Executive Officer, will be presenting...
Appoints John Purpura as interim Chief Executive Officer.Reiterates intention to announce top-line data from Phase 3 FOCUS trial by year-endAccelerates shift to commercialization planning NEW YORK, May 26, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an...
Highlights include $22 million public offering, uplisting to Nasdaq, Pivotal Registration Trial enrollment completed, and Pivotal Registration Topline Data Expected in 2020 NEW YORK, May 15, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology...
NEW YORK, May 05, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the closing of its previously announced underwritten public offering of 2.2...
NEW YORK, May 01, 2020 -- Delcath Systems, Inc. (OTCQB:DCTH NASDAQ:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the pricing of a $22 million underwritten public offering of 2.2...
NEW YORK, Feb. 19, 2020 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that Elizabeth Czerepak, a financial executive and board member with experience in pharma,...
FOCUS Top-line Results Expected Mid-2020NEW YORK, Jan. 13, 2020 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced it has completed patient enrollment...
NEW YORK, Dec. 19, 2019 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announced that the Company's Board of Directors has authorized a 1-for-700 reverse stock split of the...
NEW YORK, Dec. 03, 2019 -- Delcath Systems, Inc. (OTCQB:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that Dr. Jennifer Simpson, Ph.D., Chief Executive Officer and Ms. Barbra Keck, Chief...
NEW YORK, Oct. 22, 2019 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Reverse Stock Split reported on October 21, 2019 will be postponed per a subsequent...
NEW YORK, Oct. 18, 2019 -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company's Board of Directors has authorized a reverse stock split of the Company's...
NEW YORK, Oct. 08, 2019 -- Delcath Systems, Inc. ("Delcath," the "Company", "we", "our" or "us" (OTCQB: DCTH) will present at the MicroCap Rodeo. The conference will be held October 15-16, 2019 in Austin, Texas. Management will be available during the day on October...
NEW YORK, Sept. 23, 2019 -- Delcath Systems, Inc. ("Delcath," the "Company", "we", "our" or "us" (OTCQB: DCTH) will participate at the following upcoming investor conferences in New York: Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019,...
NEW YORK, Aug. 28, 2019 -- Delcath Systems, Inc. ("Delcath," the "Company", "we", "our" or "us" (OTCQB: DCTH) will present at the Rodman & Renshaw 21st Annual Global Investment Conference sponsored by H.C. Wainwright, at 5:05pm on Tuesday, September 10, 2019. The...
Bringing total financial amount raised since July 2019 to $29.5M Cash runway past top-line results in 1H2020 with NDA submission anticipated by end of 2020 Recapitalization provides possible path to NASDAQ listing NEW YORK, Aug. 20, 2019 -- Delcath Systems, Inc....
NEW YORK, Aug. 15, 2019 -- Delcath Systems, Inc. ("Delcath," the "Company", "we", "our" or "us" (OTCQB: DCTH)) today announced that it has entered into a definitive agreement for gross proceeds of approximately $9.5 million at a combined price of $1,000 per Unit. Each...
Seasoned leader with successful track record joins to help Delcath in the next phase of its development.NEW YORK, July 29, 2019 -- Delcath Systems, Inc. (OTC Pink: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver...
Retrospective Study by University Hospital of Tubingen Shows Median Overall Survival of 27.4 Months in Patients with Ocular Melanoma Liver MetastasesNEW YORK, July 22, 2019 -- Delcath Systems, Inc. (OTCPK: DCTH), an interventional oncology company focused on the...
NEW YORK, July 17, 2019 -- Delcath Systems, Inc. ("Delcath," the "Company", "we", "our" or "us" (OTCPK: DCTH) has closed on its previously announced private placement with gross proceeds of $20 million at a combined price of $1,000 per Unit. Each Unit consists of one...
NEW YORK, July 11, 2019 -- Delcath Systems, Inc. ("Delcath," the "Company", "we", "our" or "us") (OTCPK: DCTH) today announced that it has entered into a definitive agreement for gross proceeds of approximately $20 million at a combined price of $1,000 per Unit. Each...